FDA Grants Fast Track Designation for Tipifarnib In Patients with HNSCC

The FDA has granted a Fast Track Designation to tipifarnib, a farnesyl transferase inhibitor, for the treatment of patients with HRAS-mutant head and neck squamous cell carcinomas who have previously progressed on platinum therapy, according to a press release from Kura Oncology.

Read the full article here

Related Articles